Charles River Laboratories International, Inc. (CRL) reported a 33.3% increase in its stock shares over the past month, coinciding with improved operating trends. The company announced second-quarter 2026 non-GAAP earnings of $3.02 per share, exceeding expectations by 17.6%, despite a 3.2% year-over-year decline. Total revenues for the quarter reached $1 billion, a 2.7% decrease but above forecasts by 3%.
Management has raised its non-GAAP earnings guidance for the year to a range of $11.15-$11.45 per share, up from $10.80-$11.30. Organic revenues for the Discovery and Safety Assessment (DSA) segment saw a nominal increase of 0.2%, with net bookings rising 12.6% to $701 million.
However, the Research Models and Services (RMS) segment faced a 1.4% revenue decline, and overall, CRL’s premium valuation at 24.06X forward earnings raises operational execution pressure, as bookings need to convert effectively into revenue to sustain the recent stock rally.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
